Clinical Trials Sponsored by Sanofi-Synthélabo (Schweiz) AG

Total 3 results

Hoffmann-La Roche
Sanofi-Synthélabo (Schweiz) AG

Completed

A Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer

Rectal Cancer

Switzerland
Lund University Hospital
Roche Pharma AG; Sanofi-Synthelabo

Completed

Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer (CORGI)

Stomach Cancer | Colorectal Cancer | Pancreas Cancer | Gall Bladder Cancer | Bile Ductus Cancer

Sweden
SCRI Development Innovations, LLC
Roche Pharma AG; Sanofi-Synthelabo

Completed

Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site

Neoplasms, Unknown Primary

United States

3

Subscribe